Apogee Therapeutics, Inc. Common Stock (APGE) — Net Asset Quality Index
Apogee Therapeutics, Inc. Common Stock (APGE) has a Net Asset Quality Index of 97.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $1.29 Billion minus total liabilities of $37.86 Million yields net assets of $1.26 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Apogee Therapeutics, Inc. Common Stock (APGE) liquidity interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Apogee Therapeutics, Inc. Common Stock Net Asset Quality Index Over Time (2022–2025)
This chart shows how Apogee Therapeutics, Inc. Common Stock's Net Asset Quality Index has evolved across 4 annual periods from 2022 to 2025. As of March 2026, the index stands at 97.1%, representing net assets of $1.26 Billion against total assets of $1.29 Billion USD. Explore Apogee Therapeutics, Inc. Common Stock (APGE) cash conversion ratio to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below presents the year-by-year Net Asset Quality Index for Apogee Therapeutics, Inc. Common Stock from 2022 to 2025, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see APGE market cap.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 96.5% | $903.88 Million | $937.13 Million | $33.25 Million | ▲ +1.4 pp |
| 2024 | 95.1% | $716.79 Million | $753.95 Million | $37.16 Million | ▲ +0.4 pp |
| 2023 | 94.6% | $379.91 Million | $401.40 Million | $21.49 Million | ▲ +1.2 pp |
| 2022 | 93.4% | $142.07 Million | $152.06 Million | $9.98 Million | — |